Citigroup Begins Coverage on Elanco Animal Health (NYSE:ELAN)

Citigroup started coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research report issued to clients and investors on Wednesday. The firm set a “buy” rating and a $30.00 price target on the stock. Citigroup’s target price would suggest a potential upside of 24.38% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Leerink Partners increased their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Friday, March 27th. Finally, KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average target price of $27.90.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $24.12 on Wednesday. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $11.99 billion, a PE ratio of -50.25, a PEG ratio of 3.04 and a beta of 1.88. The stock’s fifty day simple moving average is $24.42 and its 200 day simple moving average is $23.07.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm posted $0.14 earnings per share. Elanco Animal Health’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, research analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently added to or reduced their stakes in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health during the first quarter worth $2,065,000. Goldman Sachs Group Inc. increased its stake in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its stake in Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after purchasing an additional 295,651 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.